Even if few important indications of KEAP1 genetic alterations in high grade neuroendocrine lung tumors (LCNEC) with adeno-like features came from two recent works [35,38], SCLC point mutations of KEAP1 and NFE2L2 genes remain a rare phenomenon, and the epigenetic modulation of KEAP1 expression has not yet been elucidated. This evidence concerns the gene NFE2L2 and lung neuroendocrine neoplasm.